Dozens of trials. Surging investment. Packed symposia.
The psychedelic market is moving fast! Yet the one voice whose views are likely changing fastest — the prescriber — is the least tracked.
Introducing
Psychedelic Signals: Prescribers
An ongoing multi-client “market radar” listening for how today’s US Psychiatrists think, believe, and behave regarding the use of psychedelics to treat mental disorders
The study will illuminate and track:
Overall opinions and beliefs among US Psychiatrists regarding psychedelics
Awareness and use of psychedelic therapies, unregulated and Rx
Knowledge /awareness of clinical trials and manufacturers in the space
Current perceptions of drivers and barriers of Rx adoption
Why Psychedelic Signals: Prescribers?
Replace internal “gut” opinions with objective data from front-line prescribers to drive confident decisions via a cost-efficient model.
ADDED BONUS: For our first three clients onboarded, we are offering the inclusion of 2-3 custom questions with data provided to only your organization.
A portion of proceeds from this study will be donated to Healing Cancer Journeys, a non-profit providing education to cancer patients exploring psychedelic therapies.
